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To assess the response to the reemergence of lym-
phogranuloma venereum, we conducted a cross-sectional 
survey by administering a structured questionnaire to rep-
resentatives from 26 European countries. Responses were 
received from 18 countries. The ability to respond quickly 
and the measures used for outbreak detection and control 
varied. Evidence-based criteria were not consistently used 
to develop recommendations. We did not develop criteria 
to determine the effectiveness of the recommendations. 
The degree of preparedness for an unexpected outbreak, 
as well as the ability of countries to respond quickly to 
alerts, varied, which indicated weaknesses in the ability 
to control an outbreak. More guidance is needed to imple-
ment and evaluate control measures used during interna-
tional outbreaks. 
R
esponding effectively to international communicable 
disease emergencies is a complex process that involves 
national and international cooperation. Efforts should be 
aimed at managing patient care and containing the disease 
by interrupting the chain of transmission (1,2). The severe 
acute respiratory syndrome outbreak has shown the need 
for being prepared and being able to deal with international 
emergencies in a consistent way; all countries need to be 
prepared and able to respond to an outbreak. Countries 
throughout Europe have developed preparedness plans to 
face a possible pandemic caused by a new inﬂ  uenza virus. 
But even with a well-acknowledged threat like an inﬂ  uenza 
pandemic, differences in preparedness between countries 
exist (3,4). The differences might be even greater when 
timely control measures are needed for outbreaks that re-
main unnoticed for a long time.
Systems for surveillance and outbreak management 
among European countries differ, as do their health poli-
cies and guidelines. We wondered whether these differ-
ences could lead to different outbreak control measures 
and therefore to differences in the effectiveness of these 
control measures. We studied the quality and timeliness 
of public health actions during the reemergence of lym-
phogranuloma venereum (LGV) among men who have sex 
with men (MSM) in Europe from January 2004 to Febru-
ary 2006. In January 2004, the European Surveillance of 
Sexually Transmitted Infections Network (ESSTI) issued 
an international alert. This action was considered a trigger 
for countries to identify possible cases; deﬁ  ne, inform, and 
investigate the population at risk; and to implement con-
trol measures. The resurgence of LGV in Europe contained 
many features similar to an infectious disease emergency: 
it occurred unexpectedly; there was delay in the recognition 
of cases, which allowed the disease to spread within the 
risk group; and there was no preconceived outbreak control 
plan. Moreover, in many countries, LGV is not reportable 
and surveillance is voluntary.
Our study of the response to this LGV outbreak demon-
strates the need for a uniﬁ  ed response to new, unexpected, 
infectious diseases. We assessed the similarities and differ-
ences in how various countries managed the LGV outbreak 
to identify common practices and to formulate criteria for 
improving the response to international outbreaks.
Participants and Methods
A cross-sectional survey was conducted from Octo-
ber 2005 through February 2006 among the countries par-
ticipating in ESSTI and in Switzerland. The ESSTI then 
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consisted of 22 member states of the European Union plus 
Iceland, Norway, and Turkey. Scotland was included as 
an individual respondent and participated in the network 
as such. In collaboration with the ESSTI steering group, 
we developed a structured questionnaire and sent it to each 
country’s representative (surveillance leads and reference 
microbiologists).
The items on the questionnaire were based on a frame-
work derived from the literature about outbreak manage-
ment (1,3–5). In addition, to assess the quality of the devel-
opment and implementation of key recommendations for 
controlling the outbreak, we used parts of the international 
AGREE instrument (www.agreecollaboration.org) for ap-
praising guidelines and guideline development programs.
The questionnaire was divided into 4 sections. The 
ﬁ  rst section was dedicated to the alert and initial response 
to LGV and included 8 questions about actions taken after 
the ESSTI alert, risk assessment, and occurrence of cases. 
The second section included 8 questions about the develop-
ment of outbreak control measures and gathered informa-
tion about how evidence was collected and analyzed, how 
measures were formulated, when experts were consulted, 
and how recommendations were updated. The third section 
included 9 questions about the content of outbreak control 
measures (i.e., case identiﬁ  cation, case deﬁ  nitions, labora-
tory conﬁ  rmation, treatment, reporting, and interventions 
for health professionals and the groups at risk). The fourth 
section addressed implementing outbreak control measures 
(i.e., strategies, dissemination of information, targets for 
monitoring effectiveness, and additional resources).
Questionnaires were completed electronically or on 
paper, and data were analyzed by SPSS 12.0 (Chicago, 
IL, USA). LGV is a sexually transmitted infection (STI) 
caused by Chlamydia trachomatis serovars L1, L2, and 
L3. Contrary to infection with other serovars, infections 
with C. trachomatis L1–3 are not limited to the mucosa 
but rather are often invasive and can spread to the lymph 
nodes, which results in a more severe clinical outlook. In 
industrialized countries, cases are incidentally imported 
from tropical and subtropical areas where the disease is en-
demic (6). Public health measures are usually restricted to 
contact tracing and adequate management of sex partners 
in individual cases; outbreak management is not needed. 
By the end of 2003, 13 cases had been reported to the 
public health authorities in the Netherlands, followed by 
a substantial increase in cases in subsequent months. The 
cases were seen among MSM. Clinical signs were mostly 
gastrointestinal and included proctitis, purulent or mucous 
anal discharge, and constipation (7). In the early days of the 
outbreak, the potential for international spread was recog-
nized because patients reported having had sexual contacts 
in other countries such as Belgium, the United Kingdom, 
and France (8).
To create awareness, a message was sent through the 
Early Warning and Reporting System of the European 
Union and through the ESSTI. Since then, LGV cases have 
been identiﬁ  ed in several European countries, the United 
States (9), and Canada (10). Most patients were HIV posi-
tive (11), and some were hepatitis C positive (12).
Results
The questionnaire was sent to 26 countries; 11 of 
these countries had reported outbreaks of LGV in the past. 
Completed questionnaires were received from 18 countries 
(Austria, Belgium, Denmark, Finland, France, Germany, 
Ireland, Italy, the Netherlands, Norway, Portugal, Scot-
land, Slovenia, Spain, Sweden, Switzerland, United King-
dom, and Turkey). Of the 18 questionnaires, 12 were com-
pleted by medical doctors, 4 by medical epidemiologists, 
and 2 by researchers/microbiologists. In 5 countries (Bel-
gium, Ireland, Portugal, Slovenia, and Sweden), the ques-
tionnaire was ﬁ  lled in by 2 or more experts from different 
areas of expertise. The 8 countries that did not respond to 
either the questionnaire or the electronic reminders (Slovak 
Republic, Poland, Malta, Latvia, Iceland, Cyprus, Estonia, 
and Greece) were excluded from the analysis. A complete 
overview of the activities reported for controlling LGV 
and their development and implementation is given in the 
Tables 1 and 2.
Initial Alert and Response
After the ESSTI alert in January 2004, timely na-
tional alert and response systems were set up by 11 of the 
18 responding countries. These systems included provi-
sional control guidelines (9 countries), voluntary report-
ing (9 countries), and tools for disseminating information 
to health professionals (11 countries). Of the 11 countries 
who undertook early alert and response activities, 9 also 
reported cases. The main objectives of the alert were active 
case ﬁ  nding (11 countries), assessing the size and nature 
of the outbreak (10 countries), and providing appropriate 
clinical care (9 countries). In 4 countries, the initial alert 
and response were undertaken by professionals from the 
STI surveillance system in collaboration with specialists in 
outbreak control. In the other 7 countries, only surveillance 
specialists were involved.
Development of Outbreak Control Measures
Five countries had a national outbreak management 
team or advisory committee that provided scientiﬁ  c advice 
on surveillance and outbreak management. The multidisci-
plinary outbreak management teams always included epi-
demiologists and microbiologists; less frequently included 
were molecular biologists, dermatovenereologists, geni-
tourinary specialists, and communicable disease control 
specialists. In 1 country, communication experts and social 
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scientists also participated in the outbreak management 
teams. No general practitioners, nurses, patients, or poli-
cymakers were involved in outbreak management teams. 
Of the 18 countries, control measures were aimed primar-
ily at identifying new cases (8 countries) and promoting 
awareness among the risk group (10 countries) and STI 
clinics (11 countries). A risk assessment was performed by 
8 countries.
When developing recommendations for outbreak con-
trol, criteria varied with the 18 countries (Tables 1 and 2). 
Evidence was systematically collected by literature (11 
countries) and electronic database searches (10 countries). 
Informal consensus procedures were mostly used to formu-
late recommendations (10 countries) based on experience-
based analysis of evidence (8 countries). Procedures for 
updating control measures were available in 11 countries. 
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Table 1. Control measures used by 18 European countries during an LGV outbreak* 
Category  All countries (n = 18)  Countries with cases (n = 11) 
Initial alert and response 
  Alert and response issued  11 9
  Enhanced  surveillance  8 7
  Voluntary  reporting  9 7
  Provisional  guidelines  9 7
  Information  dissemination  11 9
  Educational  activities  6 6
Development of control measures 
  Outbreak management team (advisory team)  5 5
  Initial risk assessment performed  8 7
  Methods to collect evidence 
  Hand  search  literature  11 9
  Search  electronic  databases  10 7
    Search patient entry data  7 6
  Search  unpublished  data  4 4
  Methods to analyze evidence 
  Decision  analysis  5 3
  Meta-analysis  0 0
  Nonsystematic  review  5 4
  Systematic  review  4 4
  Experience  based  8 7
  Methods to formulate measures 
  Subjective  review  8 6
  Informal  expert  consensus  10 8
  Formal  expert  consensus  4 4
  Evidence  based  0 0
  Procedure for updating key recommendations  11 4
  National LGV guideline  4 3
  Formal authorization process of the guideline  2 2
Content of control measures 
  Active case finding  9 7
 Contact  tracing  7 6
 Partner  notification  5 4
  Screening risk group  5 3
  Activities targeting risk groups  10 8
 Alerting  general  public  1 1
 Alerting  general  practitioners  8 5
  Alerting STI clinics  11 9
  Alerting public health physicians  9 9
 Alerting  microbiologists  9 6
 Alerting  hospitals  5 3
  Alerting GUM and gastroenterologists  8 6
  Alerting HIV specialists  3 3
 LGV  notifiable†  5 4
  National case-register for LGV†  9 7
*Data gathered through a survey. LGV, lymphogranuloma venereum; STI, sexually transmitted infection; GUM, genitourinary specialists. 
†Data were missing for 3 countries for this category. RESEARCH
A total of 4 countries developed national, multidisciplinary 
guidelines for LGV control, 2 of which issued authoriza-
tion procedures for the guidelines.
Content of Outbreak Control Measures
Active case ﬁ  nding was initiated by 9 countries and 
contact tracing by 7. Five countries implemented both. In-
formation activities for the group at risk were performed by 
10 countries and 11 countries alerted their STI clinics. An 
overview of all the control measures is given in the Tables 
1 and 2. A total of 11 respondents (Denmark, Germany, 
Norway, Sweden, Spain, United Kingdom, Scotland, Aus-
tria, the Netherlands, Ireland, and Belgium) used an iden-
tical case deﬁ  nition for conﬁ  rmed cases: MSM or sexual 
contacts of patients with LGV, who had anorectal or ingui-
nal syndrome and positive nucleic acid ampliﬁ  cation tests 
(NAAT) for Chlamydia trachomatis genotype L1, L2, or 
L3. From these 8 countries, case deﬁ  nitions were also is-
sued for probable and possible cases and differed widely 
according to laboratory criteria.
Laboratory diagnosis of C. trachomatis was performed 
by NAAT on the following samples: rectal swabs (12 coun-
tries), biopsy material from lesions (8 countries), urethral 
swabs (5 countries), and urine (2 countries). Genotyping 
to conﬁ  rm the presence of serovars L1–L3 was also avail-
able from 11 countries. Supplementary testing of patients 
for concurrent STIs was recommended as follows: HIV 
(8 countries), syphilis (5 countries), hepatitis C (3 coun-
tries), hepatitis B (3 countries), and Neisseria gonorrhoeae 
(2 countries).
With respect to antimicrobial therapy, various regi-
mens and different doses were used. For 9 countries doxy-
cycline (100 mg 2×/day for 21 days) was the ﬁ  rst choice of 
treatment. Alternatives mentioned were tetracycline (2 g/
day), minocycline (300 mg loading dose followed by 200 
mg 2×/day), and erythromycin (500 mg 4×/day). Clinical 
and laboratory follow-up of the patients was performed by 
10 countries.
Implementation of Outbreak Control Measures
The control measures were implemented by dissemi-
nating educational materials in 9 countries, disseminating 
national bulletins in 5, and holding meetings and confer-
ences for professionals in 3 countries. Most countries 
(11/18) had the risk group help disseminate information. 
Targets to monitor the effectiveness of recommendations 
were not formulated by any country.
Discussion
This outbreak of LGV had special features with high 
clinical and public health signiﬁ  cance. First, recognition of 
cases was difﬁ  cult due to the unusual clinical presentation 
that mimics inﬂ  ammatory bowel disease. Second, the diag-
nosis of LGV involved invasive procedures for collecting 
samples and required NAAT, which were not licensed for 
rectal specimens. Furthermore, patients mostly belonged to 
sex networks of MSM in large cities with numerous anony-
mous partners from different countries (13) and where (in-
ternational) contact tracing was difﬁ  cult. In most European 
countries, LGV is not notiﬁ  able by law so cases are likely to 
be dealt with outside the public health domain. The poten-
tial of unnoticed further spread and the risk for simultaneous 
transmission of other infections, such as HIV and syphilis, 
increased the public health importance of this outbreak.
Differences were seen between countries with respect 
to ability to rapidly respond and implement measures that 
are needed to detect or to control a possible outbreak. 
Countries that reported cases of LGV were more likely to 
recommend control measures although measures were also 
needed to detect possible cases. To identify and diagnose 
cases, clinical specialists and public health physicians, as 
well as the risk group, must be aware of the outbreak, par-
ticularly for an LGV outbreak. LGV is a rare disease in 
Europe, and often healthcare workers are not aware of the 
clinical features of the disease.
Outbreak control measures require collaboration be-
tween persons in multiple specialties, such as specialists 
in surveillance, communicable disease control, health pro-
motion, and physicians involved in the direct patient care 
(venereologists, genitourinary medicine specialists, gastro-
enterologists, microbiologists) that do not necessarily work 
together in other circumstances. In this outbreak, informa-
tion from the surveillance systems was as important for 
health providers as for policymakers; this information had 
to lead to immediate recognition of a public health threat 
and direct action.
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Table 2. Implementation of control measures used by 18 
European countries during an LGV outbreak*  
Implementation measure 
All countries
(n = 18) 
Countries with 
cases (n = 11) 
Disseminating educational 
materials
98
Conferences for professionals  3 3
National bulletins  5 4
Outreach visits  0 0
Computer reminders  0 0
Changes in medical records 
systems 
00
Changes in facilities and 
equipment
00
Additional finances  3 3
Strategy for media 
communication
65
Involvement of MSM society in 
dissemination of information 
11 8
Targets to monitor 
effectiveness
00
*Data gathered through a survey. LGV, lymphogranuloma venereum; 
MSM, men who have sex with men. Lymphogranuloma Venereum Outbreak
However, in the management of LGV patients, dif-
ferences were seen between countries with respect to case 
deﬁ  nitions, laboratory testing, and antimicrobial drug treat-
ment. With most patients belonging to international sex 
networks, uniform diagnostic procedures and treatment 
protocols would have been helpful for ensuring a uniform 
approach to outbreak control. Furthermore, control mea-
sures were impaired because in many countries LGV is 
not a notiﬁ  able disease; therefore, there is no legal basis 
for disclosing names of sexual contacts to facilitate con-
tact tracing and prevent further spread. Contact tracing was 
made even more difﬁ  cult because of the numerous anony-
mous sexual contacts in various European cities.
Criteria for evidence-based development of recom-
mendations were not always consistently used to extract 
and analyze evidence for best practices during the LGV 
outbreak, which led to differences in outbreak manage-
ment. Speciﬁ  c targets for monitoring the effectiveness of 
recommendations were not formulated by any country. One 
strong point was the acknowledgment by many countries of 
the importance of having the risk group, MSM, disseminate 
alerts and advocate awareness.
Until now, the reemergence of LGV has affected MSM 
in 11 European countries. The ESSTI alert prompted these 
countries to take action to identify cases early, improve the 
management of cases, and assess the size of the outbreak. 
Of the 18 respondents, 7 stated that they had not taken any 
action at this stage for various reasons: they did not receive 
the alert (Turkey, Slovenia) or they did not participate in 
the ESSTI (Switzerland). Coordination at the European 
level should encourage and monitor the response of all 
countries to alerts.
Our study has some limitations. We assumed that all 
countries that were participating in the ESSTI network in 
2005 had also been informed about the LGV outbreak. 
Later, it became clear that the countries that had joined the 
European Union on May 1, 2004, did not receive the ES-
STI alert. Because only 1 of these new European Union 
member countries completed the questionnaire, it was also 
impossible to assess how outbreak control measures were 
developed and implemented. Another limitation inherent to 
the method used was that not all key persons involved in 
the control of LGV were able to ﬁ  ll out the questionnaire. 
As the questionnaire was sent to the country representatives 
in the ESSTI, it is possible that not all relevant information 
was available on the control measures and activities that 
had taken place at regional or local levels. Furthermore, 
the quality of the outbreak management process and the 
development of outbreak measures could only be assessed 
indirectly on the basis of the answers to the questionnaire 
because only a few countries provided more detailed docu-
ments like guidelines or articles. The LGV outbreak is still 
ongoing in Europe, and since the completion of this study 
more countries may have undertaken measures to identify 
and treat cases and to prevent further transmission.
Our  ﬁ   ndings are helpful for understanding the re-
sponses to unexpected disease outbreaks. However, we 
do acknowledge that LGV is an STI (rather than a quick-
spreading communicable, airborne disease) and therefore, 
affects a minority of sexually active citizens (MSM) in the 
country. 
Communicable diseases differ from other health 
threats or crises because they spread from person to person. 
Therefore, problems are often not restricted to 1 country. 
Various speciﬁ  c interventions are therefore justiﬁ  ed by the 
difference in local systems, cultures, and situations. How-
ever, the principles of outbreak response are general, and 
countries can learn from each other. This study shows that 
countries have varying degrees of ability to respond quick-
ly to an unexpected outbreak; these ﬁ  ndings expose weak-
nesses in the outbreak control capacity in Europe. Although 
important steps have been taken for improvement (14), the 
quality of LGV outbreak control in Europe could beneﬁ  t 
from uniform approaches in controlling other infectious 
diseases with potential for international spread and from 
exchanging information between countries.
The challenge for the future will be to coordinate out-
break management in various countries for which continu-
ity and coherence are essential. This study shows that coor-
dination should at least aim to provide guidance as to when 
and how alerts should be implemented by various countries 
as well as to establish uniform case deﬁ  nitions and ensure 
the availability of optimal diagnostic facilities. We also 
show a lack of common strategies and that these should be 
developed with respect to treatment algorithms and con-
tact tracing. Furthermore, quality systems following the 
whole chain of outbreak management (alert, outbreak con-
trol measures, implementation, and evaluation) are needed. 
These systems should be based on standard approaches 
to outbreak management followed by external review of 
implemented measures. More international collaboration is 
needed to improve response and to ensure high standards 
of practice in managing international outbreaks and threats 
caused by emerging or reemerging STIs.
Crisis situations increase the chance of overlooking es-
sential steps in outbreak management because of time con-
straints, uncertainty, and the lack of substantial evidence 
in effective approaches to controlling new diseases. Fur-
thermore, during outbreaks, key recommendations involve 
quick decision-making by professionals who often have no 
time for reevaluation. Although this need for quick deci-
sions has been acknowledged for other threats like avian 
ﬂ  u, SARS, or bioterrorism, little experience has been ac-
quired with managing outbreaks of STIs. Our systematic 
approach could be helpful in preparing for or assessing the 
response to all kinds of public health emergencies.
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